Company Overview and News

7
In Kinross Gold's Case, Patience Is A Virtue

2018-06-18 seekingalpha
On June 12, the company indicated that it is proceeding with the initial Gilmore expansion project at its Fort Knox mine in Alaska.
KGC K

32
Kinross (KGC) Moves Ahead With Fort Knox Gilmore Expansion

2018-06-15 zacks
Kinross Gold Corporation (KGC - Free Report) said that it is proceeding with the initial Gilmore expansion project at its Fort Knox mine, Alaska. The company expects the project to extend Fort Knox’s mining by six years to 2027 and leaching to 2030 and also increase mine life production by roughly 1.5 million gold equivalent ounces. Notably, the project involves a low initial capital cost of roughly $100 million.
SPG.PRJ KGC WLK FTI.WI FMC K SPG CE

7
Kinross to proceed with initial Fort Knox Gilmore expansion

2018-06-12 globenewswire
Project expected to extend mine life to 2030 and generate 17% IRR at a low capital cost Strengthens Company’s long-term U.S. production profile
KGC K DTK

8
Kinross (KGC) Down 13.4% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
It has been about a month since the last earnings report for Kinross Gold Corporation (KGC - Free Report) . Shares have lost about 13.4% in that time frame.
KGC TBPH K

83
3 Gold Stocks That Could Bounce Back | InvestorPlace

2018-06-07 investorplace
Once again, gold stocks are struggling. The VanEck Vectors Gold Miners ETF (NYSEARCA:GDX) and the VanEck Vectors Junior Gold Miners ETF (NYSEARCA:GDJX) both have dropped about 13% from January highs. Both ETFs are down YTD as well — with performance lagging the S&P 500.
WPM TAHO FNV.WT.A ABX FNV AU K GDX SLW AULGF RGLD THO SLW KGC AGG IAG GG FNV RGL ABX GDXJ

51
Resource Sector Digest: Sandstorm Gold And The Beauty Of Depletion

2018-06-05 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
HRT MGG HRTFF MMRGF GFI.WI FNV NEM NMKEF RSG PRB RNX RNKLF KGC NMX RMGGF FQVLF AEM MACIF AG FQM GFIOF NDM WPM RPM FR SAND FNV.WT.A SSL GPL SDDXF ALO PROBF K RPMGD WHGOF RPMGF SNXZF ORG RGLD RNX.WT RMGGY GFI PGLC CANWF FNV RGL

40
Gold Is Playing Its Role as Safe Haven this Year!

2018-06-05 marketrealist
Gold and gold miners have been all over the place this year. Often, we think of gold as a safe haven and defensive play, and often it is. But sometimes it’s in its own cycle or just another asset for people to sell in times of trouble. This year, gold is playing its role as a safe haven and is up 3% during a flat and tumultuous market. But for some reason, the miners are acting more like other stocks—and, at some periods, even worse than the market.
ABX KGC NEM K ABX

9
Orca Gold Inc. Announces Closing of First Tranche of Strategic Investment by Resolute Mining Limited

2018-05-31 globenewswire
VANCOUVER, B.C., May 31, 2018 (GLOBE NEWSWIRE) -- Orca Gold Inc. (TSX-V:ORG) (“Orca” or the “Company”) is pleased to announce that it has closed the first of two tranches of its previously announced private placement (see Company news release on May 28, 2018). The Company has issued 16,182,480 common shares (“Shares”) to a subsidiary of Resolute Mining Limited (“Resolute”) at a price of C$0.675 per Share for gross proceeds of C$10,923,174.
RSG KGC RMGGY RMGGF K CANWF ORG

38
Zacks Industry Outlook Highlights: Franco-Nevada, Sandstorm, IAMGOLD and Kinross

2018-05-31 zacks
Chicago, IL – May 31, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Franco-Nevada Corp. (FNV - Free Report) , Sandstorm Gold Ltd. (SAND - Free Report) , IAMGOLD Corp. (IAG - Free Report) and Kinross Gold Corp. (KGC - Free Report) .
SAND SSL SDDXF TXN MATW K SNXZF ALIMR IMMR KGC DG XOXO XOMA IAG FNV

24
Crispr Therapeutics stock plunges 14% premarket after FDA halts NDA for sickle-cell disease treatment

2018-05-31 marketwatch
Crispr Therapeutics and Vertex Pharmaceuticals Inc. said late Wednesday the U.S. Food and Drug Administration has put a hold on a new-drug application for a drug used for the treatment of sickle-cell disease, "pending the resolution of certain questions that will be provided by the FDA as part of its review." The application was filed in April ahead of trials in adult patients, they said. The companies said they expect "additional information" from the FDA shortly and plan to work with the agency "toward a resolution.
MANT SRLP VRTX ASTE GMLP KGC CRSP K

46
Affluent Asia, U.S. & Other Factors Likely to Sustain Gold

2018-05-30 zacks
In the current unstable financial climate, the need to reduce one’s susceptibility against changing economic fortunes has become a top priority for investors. This is where the safe-haven appeal of gold becomes alluring and often acts as a cushion to fall back on. In contrast to more volatile stock market investments, gold has always been valued as a solid and dependable means to protect wealth.
WFC WFCNP WFC.WS SAND SSL SDDXF WFC.PRL K WFC.PRJ SNXZF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP KGC WFC.PRO WFC.PRN WFC.PRY WFC.PRX IAG WFC.PRW FNV WFC.PRV

49
Which Gold Miners Could Show Upside Potential after Q1 2018?

2018-05-30 marketrealist
Gold prices have been volatile so far this year. After reaching a peak of $1,360 per ounce in January, the price fell below $1,300 per ounce in May. Year-to-date, the SPDR Gold Shares (GLD), which tracks physical gold prices, has fallen ~1% and underperformed the broader markets. The SPDR S&P 500 ETF (SPY), which tracks the S&P 500 Index, has risen 2.2%, while the PowerShares QQQ ETF (QQQ), which tracks the technology-heavy Nasdaq Composite Index, has risen 9.
ABX O87 KGC NEM K GDX GLD ABX

40
Which Gold Miners Beat and Which Ones Missed in Q1 2018?

2018-05-30 marketrealist
Among the gold miners (RING) (GDX) we’re looking at in this series, only Goldcorp (GG) missed analysts’ earnings expectations. The reaction to the beats and misses and the extent of gold beats and misses varied among miners. In the broader equities market in the S&P 500 (SPY), 78% of miners that have released their first-quarter results have reported a positive earnings surprise, while 77% have reported a positive sales surprise.
ABX KGC NEM K ABX

26
White Gold Corp. Commences 20,000m Drill Program with Drilling Underway on White Gold and Betty Properties

2018-05-30 globenewswire
TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- White Gold Corp. (TSX.V:WGO) (OTC – Nasdaq Intl:WHGOF) (FRA:29W) (the "Company") is pleased to announce commencement of the 2018 drill program on its extensive land package representing approximately 40% of the White Gold District in Yukon, Canada. The Company has initiated drilling on two of it’s highest priority properties, with diamond and reverse circulation (“RC”) drilling on the White Gold property and rotary air blast (“RAB”) drilling on the Betty property.
AEM KGC K AEM WHGOF GG

40
Zacks Industry Outlook Highlights: Franco-Nevada, Sandstorm, IAMGOLD and Kinross

2018-05-30 zacks
Chicago, IL – May 30, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Franco-Nevada Corp. (FNV - Free Report) , Sandstorm Gold Ltd. (SAND - Free Report) , IAMGOLD Corp. (IAG - Free Report) and Kinross Gold Corp. (KGC - Free Report) .
HD SAND SSL SDDXF TXN K SNXZF KGC GM.WS.A GM.WS.B GM.WS.C GM GM.WSB IAG FNV

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:K / Kinross Gold Corp. on message board site Silicon Investor.

World Outlook Franklin, Andrews, Kramer u0026 Edelstein
Marijuana Stocks Charts for Breakout II
Bottom Fish Stocks (Between .05 and $5) Taking Advantage of a Sharply Changing Environment
Heart Attacks, Cancer and strokes. Preventative approaches 2026 TeoTwawKi ... 2032 Darkest Interregnum
Technology Stocks u0026 Market Talk With Don Wolanchuk The *NEW* Frank Coluccio Technology Forum